Ítem
Solo Metadatos
Clinical efficacy of botulinum toxin type A reconstituted and refrigerated 1 week before its application in external canthus dynamic lines
Título de la revista
Autores
Lizarralde, Mónica
Gutiérrez, Sara Helena
Venegas, Adriana
Resumen
BACKGROUND: Allergan Inc. recommends that its botulinum toxin type A (BTX-A; BOTOX) must be refrigerated and applied within 4 hours after its reconstitution to avoid losing its biologic effectiveness. OBJECTIVE: The objective was to compare clinical efficacy in treating external canthus dynamic lines with reconstituted and refrigerated toxin (BTX-A) 1 week before its application versus fresh toxin (BTX-A). METHODS: This study was a double-blind, randomized, clinical trial. A total of 30 patients aged 30 to 60 years having a minimum of one and maximum of six external canthus dynamic lines were treated in one canthus with 15 U of BTX-A reconstituted and refrigerated at 4°C 1 week before being applied and in the other with 15 U of fresh BTX-A. Patients were followed-up on Day 10 and Weeks 6, 12, and 18; assessment included a neuroconduction study of the facial nerve and the investigators' photographic evaluation of the number of external canthus dynamic lines at maximum smile. RESULTS: Outcome measurement did not show statistically significant differences between both groups. CONCLUSION: BTX-A, reconstituted and refrigerated 1 week before its application, has similar clinical efficacy in treating external canthus dynamic lines as does fresh BTX-A. © 2007 by the American Society for Dermatologic Surgery, Inc.
Abstract
Introduction: Central pain is one type of pain that occurs in patients with Parkinson's disease (PD). Because of its low incidence and prevalence, it often goes unnoticed and affected patients do not therefore receive adequate analgesic therapy, which increases their suffering. It is a burning pain with spontaneous onset and periods of exacerbation; pain is poorly localised and usually more intense on the more affected side. Its pathophysiology on patients with PD is not clearly defined. Methods: We performed a search and systematic selection of all clinical studies published from January 1986 to September 2010 concerning central neuropathic pain in Parkinson's disease. Conclusions: Treatment with L-Dopa has not been demonstrated to have an analgesic effect on this type of pain. Future studies are required to improve our understanding of this condition, and to develop interventions for preventing and treating it. © 2011 Sociedad Española de Neurología.
Palabras clave
Keywords
Botulinum toxin A , Botulinum toxin A , Adult , Article , Clinical trial , Controlled clinical trial , Controlled study , Double blind procedure , Drug efficacy , Eyelid , Facial nerve , Female , Follow up , Freezing , Human , Male , Nerve conduction , Priority journal , Randomized controlled trial , Dilution , Drug potency , Drug stability , Note , Adult , Botulinum Toxin Type A , Double-Blind Method , Drug Administration Schedule , Drug Storage , Face , Female , Humans , Male , Middle Aged , Neuromuscular Agents , Refrigeration , Skin Aging
